# PACT-15 (NCT01150630)

> Gemcitabine, Cisplatin, Epirubicin, and Capecitabine in Treating Patients With Stage I-II Resectable Pancreatic Cancer

No report yet. It can be ordered.

- Drugs tested: PEXG
- Indication: resectable pancreatic adenocarcinoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT01150630
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: IRCCS San Raffaele
- Conditions: Pancreatic Cancer
- Interventions: capecitabine; cisplatin; epirubicin; gemcitabine
- Enrollment: 98
- Primary outcome: Event-free survival at 1 year (phase II)

## Indexed commentary on PACT-15 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 5

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=pact-15-nct01150630